Did Natco Blunder In Launching Sprycel Copies In India? Patent Experts Debate Pros And Cons
This article was originally published in PharmAsia News
Executive Summary
By allegedly violating court injunctions, Natco may have negated its chance for a win against Bristol-Myers Squibb in a key pharmaceutical patent case.